CTLA-4: new insights into its biological function and use in tumor immunotherapy
- PMID: 12087419
- DOI: 10.1038/ni0702-611
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Abstract
The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.
Similar articles
-
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.Annu Rev Immunol. 2001;19:565-94. doi: 10.1146/annurev.immunol.19.1.565. Annu Rev Immunol. 2001. PMID: 11244047 Review.
-
Expression and functional significance of CTLA-4, a negative regulator of T cell activation.Arch Immunol Ther Exp (Warsz). 2001;49(1):39-46. Arch Immunol Ther Exp (Warsz). 2001. PMID: 11266089 Review.
-
Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.Cancer Res. 1997 Sep 15;57(18):4036-41. Cancer Res. 1997. PMID: 9307290
-
Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability.J Immunol. 1997 May 1;158(9):4074-81. J Immunol. 1997. PMID: 9126965
-
Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population.Nat Med. 2000 Feb;6(2):211-4. doi: 10.1038/72323. Nat Med. 2000. PMID: 10655112
Cited by
-
Strategies to reverse melanoma-induced T-cell dysfunction.Clin Dermatol. 2013 May-Jun;31(3):251-6. doi: 10.1016/j.clindermatol.2012.08.010. Clin Dermatol. 2013. PMID: 23608444 Free PMC article.
-
Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis.PLoS One. 2020 Aug 6;15(8):e0237143. doi: 10.1371/journal.pone.0237143. eCollection 2020. PLoS One. 2020. PMID: 32760165 Free PMC article. Clinical Trial.
-
Melanoma immunotherapy dominates the field.Ann Transl Med. 2016 Jul;4(14):269. doi: 10.21037/atm.2016.06.32. Ann Transl Med. 2016. PMID: 27563656 Free PMC article. Review.
-
Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".Br J Cancer. 2023 Feb;128(3):461-467. doi: 10.1038/s41416-022-01960-x. Epub 2022 Sep 6. Br J Cancer. 2023. PMID: 36068276 Free PMC article. Review.
-
Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities.Front Immunol. 2012 May 4;3:103. doi: 10.3389/fimmu.2012.00103. eCollection 2012. Front Immunol. 2012. PMID: 22566975 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources